Pathogen-specific aAPC

Phase 1Biologic

SShenzhen Geno-Immune Medical Institute

Pathogen-specific aAPC is one of 19 biologic programs targeting COVID-19. It is currently in Phase 1.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

COVID-19Active, not recruiting

COVID-19 InfectionRecruiting

COVID-19Phase 1

Active, not recruiting

COVID-19 InfectionPhase 1

Recruiting

Competition

Competitive Landscape

1931 competitors in COVID-19

#DrugCompanyPhaseTrials

Singulair

AstraZeneca

Preclinical

1 2

Nexavar

Bayer

Preclinical

1 3

Proventil

Mylan Pharmaceuticals Inc

Preclinical

1 4

Benadryl

PParkedale

Preclinical

1 5

Achromycin V

WWyeth-Lederle Vaccines

Statins

1 7

Antihypertensive Agents

NNational Heart, Lung, and Blood Institute (NHLBI)

Preclinical

1 8

Pathogen-specific aAPC

SShenzhen Geno-Immune Medical Institute

Phase 1

2 9

Standard Preparation

LLondon Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

Preclinical

1 10

Moderna COVID-19 Vaccine

Moderna

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2030

Phase 1Recruiting

COVID-19 Infection

NCT04299724

PreclinicalRecruiting

Infection

NCT03159364

Clinical

Trials by Indication[1]

COVID-19 Infection1 trial

Safety and Immunity Evaluation of A Covid-19 Coronavirus Artificial Antigen Presenting Cell Vaccine

Recruiting·SShenzhen Geno-Immune Medical Institute·Phase 1·NCT04299724·100 enrolled

Infection1 trial

Phase I/II Multicenter Trial of Antigen-specific Cytotoxic T Cells in the Treatment of Opportunistic Infections

Recruiting·SShenzhen Geno-Immune Medical Institute·Preclinical·NCT03159364·100 enrolled

Sources

References

[1]
ClinicalTrials.gov — 2 trial records for Pathogen-specific aAPC. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Pathogen-specific aAPC compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Pathogen-specific aAPC. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Shenzhen Geno-Immune Medical Institute company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 1[1]
Company: SShenzhen Geno-Immune Medical Institute

Pathogen-specific aAPC

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2030

Trials by Indication[1]

COVID-19 Infection1 trial

Infection1 trial

References

Drug Info

Quick Facts

Related News